Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3633

Sort by

Sort Order Select

Journal Articles

The journey of a thousand miles begins with 1 step

Luca Malcovati

Blood (2021) 138 (10): 824–826.

https://doi.org/10.1182/blood.2021012304

Published: 2021

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Leukemia secondary to myeloproliferative neoplasms

Andrew J. Dunbar, Raajit K. Rampal, Ross Levine

Blood (2020) 136 (1): 61–70.

https://doi.org/10.1182/blood.2019000943

Published: 2020

Journal Articles

Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation

Robert Zeiser

Blood (2020) 135 (19): 1609.

https://doi.org/10.1182/blood.2020005811

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Régis Peffault de Latour, Sylvie Chevret, Anna Lisa Ruggeri, Felipe Suarez, Laetitia Souchet, David Michonneau, Flore Sicre de Fontbrune, Tereza Coman, Nathalie Dhedin, Marie Thérèse Rubio, Stéphanie Nguyen, Mohamad Mohty, Gérard Socié

Blood (2020) 135 (3): 227–229.

https://doi.org/10.1182/blood.2019000358

Published: 2020

Includes: Supplemental data

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

Liana E Gynn, BSc, Elizabeth Anderson, PhD, Gareth M Robinson, PhD, Sarah Anne Wexler, MBBS, MRCP, FRCPath, Gillian Upstill-Goddard, Christine Cox, Rhys Gareth Morgan, PhD, Jennifer E May, PhD BSc

Blood (2019) 134 (Supplement_1): 2492.

https://doi.org/10.1182/blood-2019-122891

Published: 2019

Journal Articles

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Rachael F. Grace, MD, Paola Bianchi, BSc, PhD, Bertil Glader, MD PhD, Andreas Glenthøj, MD PhD, Bryan Jones, PhD, Hitoshi Kanno, MD PhD, Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB ChB, Eduard J. van Beers, MD PhD, Joan-Lluis Vives Corrons, MD PhD, Tu Xu, MS, PhD

Blood (2019) 134 (Supplement_1): 2223.

https://doi.org/10.1182/blood-2019-123059

Published: 2019

Journal Articles

TRAF1-ALK Fusion Predicts Poor Prognosis for ALK Positive Anaplastic Large Cell Lymphoma Patients with Chemotherapy and ALK Inhibitor

Ling Huang, MD, Xinmiao Jiang, MD, Hanguo Guo, Liu Sichu, MD, Xiaojuan Wei, Chen Feili, MD, Zhanli Liang, Wenyu Li, MD PhD

Blood (2019) 134 (Supplement_1): 5224.

https://doi.org/10.1182/blood-2019-126541

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Ani Gvajaia, MD, Amelia Langston, MD, Natia Esiashvil, MD, Michael Graiser, PhD, Kelly Valla, PharmD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5657.

https://doi.org/10.1182/blood-2019-122467

Published: 2019

Journal Articles

Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy

Blood (2019) 134 (Supplement_1): 5490.

https://doi.org/10.1182/blood-2019-126057

Published: 2019

Journal Articles

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

Panayotis Kaloyannidis, Hussin Alsubaie, MD, Rawan Omari, MD, Solaf Kanfar, MD, Zahra Abdrabalamir Alshammasi, MD, Mohammed Darweesh, MD, Enas Mutahar, MD, Kenana Ajlan, Technician, Abdulhamid Liacini, Norah Muhlem, Technician, Ahmed Bahrani, MD, Afra Dayel, MD, John Apostolidis, MD, Hani Al Hashmi, MD, Khalid Ahmed Al-Anazi, MD

Blood (2019) 134 (Supplement_1): 5681.

https://doi.org/10.1182/blood-2019-128651

Published: 2019

Journal Articles

ST2 and Rg3a As a Biomarker for Predicting of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Hakan Goker, MDPROF., Elifcan Aladag, MD, Yahya Buyukasik, MD, Nelson J. Chao, MD, Umit Akman, Bio., Haluk Demiroglu, MDPROF.

Blood (2019) 134 (Supplement_1): 5684.

https://doi.org/10.1182/blood-2019-121682

Published: 2019

Journal Articles

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Moritz Bewarder, MD, Gerhard Held, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, MD, Arne Felbel, Dominic Kaddu-Mulindwa, MD, Niels Murawski, MD, Stephan Stilgenbauer, Frank Neumann, PhD

Blood (2019) 134 (Supplement_1): 5616.

https://doi.org/10.1182/blood-2019-126998

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The journey of a thousand miles begins with 1 step

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Leukemia secondary to myeloproliferative neoplasms

Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

TRAF1-ALK Fusion Predicts Poor Prognosis for ALK Positive Anaplastic Large Cell Lymphoma Patients with Chemotherapy and ALK Inhibitor

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

ST2 and Rg3a As a Biomarker for Predicting of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only